William Robinson Endowed Chair in Cancer Research at the University of Colorado Cancer Center, Sapna Patel MD, reviews recent studies on adjuvant immunotherapy in high-risk cutaneous squamous cell carcinoma (CSCC), highlighting mixed results from the KEYNOTE-630 trial and promising findings from the C-POST trial. While pembrolizumab showed no significant benefit, cemiplimab demonstrated a 68% reduction in recurrence risk, though concerns about side effects remain.